CoChat
Sign Up
Cited by 76Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis

Open access
Song, Xiaoyan, Jia, Hetang, Jiang, Yuebo, Wang, Liang, Zhang, Yan, Mu, Yiming, Liu, Yu·2015·Scientific Reports
DOI 10.1038/srep10202PMC PMC4481643
Open this paper in CoChat — free accountOpen PDF

Abstract

This study assessed the effect of GLP-1 based therapies on atherosclerotic markers in type 2 diabetes patients. 31 studies were selected to obtain data after multiple database searches and following inclusion and exclusion criteria. Age and BMI of the participants of longitudinal studies were 59.8 ± 8.3 years and 29.2 ± 5.7 kg/m 2 (Mean±SD). Average duration of GLP-1 based therapies was 20.5 weeks. Percent flow-mediated diameter (%FMD) did not change from baseline significantly but when compared to controls, %FMD increased non-significantly following GLP-1-based therapies (1.65 [−0.89, 4.18]; P = 0.2; REM) in longitudinal studies and increased significantly in cross sectional studies (2.58 [1.68, 3.53]; P < 0.00001). Intima media thickness decreased statistically non-significantly by the GLP-1 based therapies. GLP-1 based therapies led to statistically significant reductions in the serum levels of brain natriuretic peptide (−40.16 [−51.50, −28.81]; P < 0.0001; REM), high sensitivity c-reactive protein (−0.27 [−0.48, −0.07]; P = 0.009), plasminogen activator inhibitor-1 (−12.90 [−25.98, 0.18]; P=0.05), total cholesterol (−5.47 [−9.55, −1.39]; P = 0.009), LDL-cholesterol (−3.70 [−7.39, −0.00]; P = 0.05) and triglycerides (−16.44 [−25.64, −7.23]; P = 0.0005) when mean differences with 95% CI in the changes from baselines were meta-analyzed. In conclusion, GLP-1-based therapies appear to provide beneficial effects against atherosclerosis. More randomized data will be required to arrive at conclusive evidence.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep10202

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous meta-analyses of observational and randomised studies have demonstrated a reduction in CRP associated with GLP-1RAs.

    “Previous meta-analyses of observational and randomised studies have demonstrated a reduction in CRP associated with GLP-1RAs, 89,90”

    From <scp>Glucagon‐like peptide‐1 receptor agonists</scp> improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials (2021) · cites this paper as [89]

    The Results report a significant reduction in hsCRP, and the Discussion says the included longitudinal studies comprised randomized trials and non-randomized observational studies. But the Discussion defines the pooled GLP-1-based therapies as including both GLP-1 receptor agonists and DPP-4 inhibitors; it does not establish the CRP reduction specifically for GLP-1RAs. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 52

  1. Danaei G, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 378, 31– 40 (2011). 21705069
  2. Green J. & Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc. Health. Risk. Manag. 4, 743– 751 (2008). 19065992 PMC2597758
  3. Steinberger J. & Daniels S. R. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation. 107, 1448– 53 (2003). 12642369
  4. Mita T. & Watada H. Glucagon like peptide-1 and atherosclerosis. Cardiovas. Hematol. Agents. Medicinal. Chem. 10, 309– 318 (2012). 22827292
  5. Petrie J. R. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc. Diabetol. 12, 130 (2013). 24011363 PMC3847044
  6. Holst J. J., Vilsboll T. & Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol. Cell. Endocrinol. 297, 127– 136 (2009). 18786605
  7. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr. J. 58, 69– 73 (2011). 21206136
  8. Satoh-Asahara N., et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 62, 347– 351 (2013). 23062489
  9. Liu L., et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60, 833– 841 (2012). 22868389
  10. Fadini G.P., et al. Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic. Res. Cardiol. 108, 313 (2013). 23184393
  11. Rieg T., et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am. J. Physiol. Renal. Physiol. 303, F963– F971 (2011). 22832924 PMC3469689
  12. Ayaori M., et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J. Am. Heart. Assoc 2, e003277. (2013). 23525426 PMC3603233
  13. Barbieri M., et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 227, 349– 354 (2013). 23375680
  14. Bergenstal R.M., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 376, 431– 9 (2010). 20580422
  15. Bunck M.C., et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes. Care. 33, 1734– 1737 (2010). 20424219 PMC2909051
  16. Courreges J.P., et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med. 25, 1129– 1131 (2008). 19183322 PMC2592347
  17. Derosa G., et al. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes. Diabet. Med. 31, 1515– 23 (2014). 24824633
  18. Forst T., et al. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet. Med. 29, 1115– 1118 (2012). 22288732
  19. Irace C., et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab. Vasc. Dis. Res. 10, 72– 77 (2013). 22732108
  20. Ishikawa S., et al. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. Am. J. Cardiol. 114, 384– 388 (2014). 24929624
  21. Juntti-berggren L., et al. The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients. Diadetes. Care. 19, 1200– 1206 (1996). 8908380
  22. Kaku K., Itayasu T., Hiroi S., Hirayama M. & Seino Y. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes. Obes. Metab. 13, 1028– 1035 (2011). 21682833
  23. Kaku K., Rasmussen M. F., Clauson P. & Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes. Obes. Metab. 12, 341– 347 (2010). 20380655
  24. Kelly A. S., Bergenstal R. M., Gonzalez-Campoy J. M., Katz H. & Bank, A.J. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc. Diabetol. 11, 64 (2012). 22681705 PMC3434036
  25. Makdissi A., et al. Sitagliptin exerts an antinflammatory action. J. Clin. Endocrinol. Metab. 97, 3333– 3341 (2012). 22745245 PMC3431580
  26. Nakamura K., et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc. Diabetol. 13, 110 (2014). 25074318 PMC4149239
  27. Nandy D., et al. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab. Vasc. Dis. Res. 11, 419– 30 (2014). 25212693
  28. Nauck M., et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes. Metab. 15, 204– 212 (2013). 22985213
  29. Seino Y., Rasmussen M.F., Nishida T. & Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr. Med. Res. Opin. 26, 1013– 1022 (2010). 20199137
  30. Hopkins N.D., et al. Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients. Diabetes Obes. Metab. 15, 770– 773 (2013). 23451821
  31. Inoue K., et al. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol. Metab. Syndr. 6, 95 (2014). 25237400 PMC4167135
  32. Kubota Y., et al. The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes. J. Korean. Med. Sci. 27, 1364– 1370 (2012). 23166419 PMC3492672
  33. Rizzo M., et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc. Diabetol. 13, 49 (2014). 24559258 PMC3948058
  34. Ceriello A., Esposito K., Testa R., Bonfigli A.R., Marra M., et al. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care 34, 697– 702 (2011). 21273492 PMC3041210
  35. Ceriello A., et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care 37, 1938– 1943 (2014). 24667461
  36. Ceriello A., et al. Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes. Diabetes. Care. 36, 4104– 4108 (2013a). 24130351 PMC3836129
  37. Ha S.J., et al. Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler. Thromb. Vasc. Biol. 32, 474– 480 (2012). 22155457
  38. Noda Y., et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc. Diabetol. 12, 8 (2013). 23298374 PMC3557163
  39. Nystrom T., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Lancet. Diabetes. Endocrinol. 2, 691– 700 (2014). 15353407
  40. Sivertsen J., Rosenmeier J., Holst J. J. & Vilsboll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat. Rev. Cardiol. 9, 209– 222 (2012). 22290234
  41. Basu A., Charkoudian N., Schrage W., Rizza R. A., Basu R.,& Joyner M. J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab. 293, E1289– 95 (2007). 17711996
  42. Subaran S. C., et al. GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin. Sci. (Lond). 127, 163– 70 (2014). 24552454 PMC4353574
  43. Aminbakhsh A.,& Mancini G. B. Carotid intima media thickness measurements: What defines an abnormality? A systematic review. Clin. Invest. Med. 22, 149– 157 (1999). 10497713
  44. Cheng J. M., et al. Relation of c-reactive protein to coronary plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovascular outcome in patients with acute coronary syndrome or stable angina pectoris (from the ATHEROREMO-IVUS Study). Am. J. Cardiol. 114, 1497– 503 (2014). 25248815
  45. Ridker P. M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J. Am. Coll. Cardiol. 49, 2129– 38 (2007). 17531663
  46. Cybulsky M. I., Gimbrone M. A. Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251, 788– 791(1991). 1990440
  47. Couffinhal T., Duplaa C., Moreau C., Lamaziere J. M. & Bonnet J. Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circ. Res. 74, 225– 234 (1994). 7507414
  48. Liu H., Dear A. E., Knudsen L. B. & Simpson R. W. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J. Endocrinol. 201, 59– 66 (2009). 19136619
  49. Ashley K.E., Galla J.M. & Nicholls S.J. Brain natriuretic peptides as biomarkers for atherosclerosis. Prev. Cardiol. 11, 172– 176 (2008). 18607154
  50. Svensson P., de Faire U., Niklasson U., Hansson L.O. & Ostergren J. Plasma NT-pro-BNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. Blood. Press. 14, 99– 106 (2005). 16036487
  51. Jin Q., et al. Levels of brain natriuretic peptide are associated with peripheral arterial disease in subjects with type-2 diabetes mellitus. BMC Endocrine Disorders 14, 27 (2014). 24655436 PMC3998194
  52. Blaha M., et al. Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity. Physiol. Res. 53, 273– 278 (2004). 15209534

Cited by

Sorted by citations

Authors
Song, X., Jia, H., Jiang, Y., Wang, L., Zhang, Y., Mu, Y., & Liu, Y.
Affiliations
  • Chinese PLA General Hospital (CN)
  • The 309th Hospital of Chinese People's Liberation Army (CN)
Corresponding author
  • Mu, Yiming
  • Liu, Yu
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2015-06-26
Volume
5
Issue
1
Pages
10202-10202
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/srep10202
PMC
PMC4481643
OpenAlex
W2258010815
Cited by
76
References
3
Citations by year
2026: 7 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 5 · 2020: 9 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 4 · 2015: 1
FWCI
1.01
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (20123, 81270424, 30801201)
  • Beijing Nova Program
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, type 2 diabetes, atherosclerosis, atherosclerotic plaque, flow-mediated dilation, carotid intima-media thickness, brain natriuretic peptide, C-reactive protein, plasminogen activator inhibitor-1, lipid profile, LDL cholesterol, triglycerides, total cholesterol
MeSH terms
Aged, C-Reactive Protein, Cholesterol, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Databases, Factual, Plasminogen Activator Inhibitor 1, Natriuretic Peptide, Brain, Glucagon-Like Peptide 1, Carotid Intima-Media Thickness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review